Medivir AB (publ)

OM:MVIR Stock Report

Market Cap: SEK 265.8m

Medivir Valuation

Is MVIR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MVIR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MVIR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MVIR's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MVIR?

Key metric: As MVIR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MVIR. This is calculated by dividing MVIR's market cap by their current revenue.
What is MVIR's PS Ratio?
PS Ratio37.8x
SalesSEK 7.03m
Market CapSEK 265.84m

Price to Sales Ratio vs Peers

How does MVIR's PS Ratio compare to its peers?

The above table shows the PS ratio for MVIR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average16.3x
ONCO Oncopeptides
11.8x92.1%SEK 319.3m
ALZ Alzinova
16x6.8%SEK 278.2m
NICA Nanologica
11.8x79.5%SEK 178.5m
NXTCL NextCell Pharma
25.7x116.8%SEK 242.7m
MVIR Medivir
37.8x49.1%SEK 265.8m

Price-To-Sales vs Peers: MVIR is expensive based on its Price-To-Sales Ratio (37.8x) compared to the peer average (16.3x).

Price to Sales Ratio vs Industry

How does MVIR's PS Ratio compare vs other companies in the SE Biotechs Industry?

9 CompaniesPrice / SalesEstimated GrowthMarket Cap
XBRANE Xbrane Biopharma
1.2x58.0%US$23.21m
SPRINT Sprint Bioscience
1.6x1.2%US$9.95m
ATORX Alligator Bioscience
0.5xn/aUS$2.84m
GEAN Genetic Analysis
1.3xn/aUS$2.35m
MVIR 37.8xIndustry Avg. 13.1xNo. of Companies9PS01224364860+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MVIR is expensive based on its Price-To-Sales Ratio (37.8x) compared to the Swedish Biotechs industry average (13.1x).

Price to Sales Ratio vs Fair Ratio

What is MVIR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MVIR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio37.8x
Fair PS Ratio0.00007x

Price-To-Sales vs Fair Ratio: MVIR is expensive based on its Price-To-Sales Ratio (37.8x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MVIR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 2.37
SEK 20.73
+774.6%
92.8%SEK 54.00SEK 8.00n/a4
Feb ’26SEK 2.85
SEK 20.73
+627.3%
92.8%SEK 54.00SEK 8.00n/a4
Jan ’26SEK 2.84
SEK 20.73
+629.8%
92.8%SEK 54.00SEK 8.00n/a4
Dec ’25SEK 2.87
SEK 20.71
+621.7%
92.9%SEK 54.00SEK 8.00n/a4
Nov ’25SEK 2.78
SEK 20.80
+648.2%
92.2%SEK 54.00SEK 9.00n/a4
Oct ’25SEK 2.91
SEK 20.80
+614.8%
92.2%SEK 54.00SEK 9.00n/a4
Sep ’25SEK 3.18
SEK 20.80
+554.1%
92.2%SEK 54.00SEK 9.00n/a4
Aug ’25SEK 3.01
SEK 20.91
+594.6%
91.4%SEK 54.00SEK 9.00n/a4
Jul ’25SEK 2.96
SEK 20.91
+606.3%
91.4%SEK 54.00SEK 9.00n/a4
Jun ’25SEK 3.23
SEK 20.62
+538.3%
93.6%SEK 54.00SEK 8.00n/a4
May ’25SEK 3.15
SEK 20.55
+552.5%
94.1%SEK 54.00SEK 7.75n/a4
Apr ’25SEK 2.75
SEK 20.55
+648.1%
94.1%SEK 54.00SEK 7.75n/a4
Mar ’25SEK 3.08
SEK 20.55
+567.3%
94.1%SEK 54.00SEK 7.75n/a4
Feb ’25SEK 3.18
SEK 22.56
+609.5%
82.2%SEK 54.00SEK 7.75SEK 2.854
Jan ’25SEK 2.85
SEK 21.46
+652.9%
78.8%SEK 50.00SEK 7.75SEK 2.844
Dec ’24SEK 4.15
SEK 29.24
+604.6%
47.3%SEK 50.00SEK 15.50SEK 2.874
Nov ’24SEK 7.15
SEK 29.24
+309.0%
47.3%SEK 50.00SEK 15.50SEK 2.784
Oct ’24SEK 7.06
SEK 27.95
+296.1%
53.5%SEK 50.00SEK 13.00SEK 2.914
Sep ’24SEK 7.20
SEK 27.49
+281.8%
53.8%SEK 50.00SEK 13.00SEK 3.184
Aug ’24SEK 7.24
SEK 27.99
+286.5%
51.2%SEK 50.00SEK 15.00SEK 3.014
Jul ’24SEK 7.15
SEK 27.99
+291.7%
51.2%SEK 50.00SEK 15.00SEK 2.964
Jun ’24SEK 7.01
SEK 27.99
+299.1%
51.2%SEK 50.00SEK 15.00SEK 3.234
May ’24SEK 7.58
SEK 27.99
+269.2%
51.2%SEK 50.00SEK 15.00SEK 3.154
Apr ’24SEK 8.00
SEK 27.99
+249.8%
51.2%SEK 50.00SEK 15.00SEK 2.754
Mar ’24SEK 8.45
SEK 24.57
+190.7%
59.0%SEK 50.00SEK 11.00SEK 3.085
Feb ’24SEK 9.34
SEK 24.65
+164.0%
59.0%SEK 50.00SEK 11.00SEK 3.185
Analyst Price Target
Consensus Narrative from 4 Analysts
SEK 20.73
Fair Value
88.6% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/15 22:33
End of Day Share Price 2025/02/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medivir AB (publ) is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Morten LarsenABG Sundal Collier
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB
Revi MehrotraCredit Suisse